GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (FRA:AM6) » Definitions » Market Cap

Amicus Therapeutics (FRA:AM6) Market Cap : €2,398.1 Mil (As of Mar. 29, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amicus Therapeutics's share price for the quarter that ended in Dec. 2024 was €9.15. Amicus Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 299.0 Mil. Therefore, Amicus Therapeutics's market cap for the quarter that ended in Dec. 2024 was €2,736.2 Mil.

Amicus Therapeutics's quarterly market cap increased from Jun. 2024 (€2,712.3 Mil) to Sep. 2024 (€2,822.6 Mil) but then declined from Sep. 2024 (€2,822.6 Mil) to Dec. 2024 (€2,736.2 Mil).

Amicus Therapeutics's annual market cap increased from Dec. 2022 (€3,134.4 Mil) to Dec. 2023 (€3,875.4 Mil) but then declined from Dec. 2023 (€3,875.4 Mil) to Dec. 2024 (€2,736.2 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amicus Therapeutics's Enterprise Value for Today is €2,577.4 Mil.


Amicus Therapeutics Market Cap Historical Data

The historical data trend for Amicus Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Market Cap Chart

Amicus Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,795.75 2,928.59 3,134.35 3,875.44 2,736.23

Amicus Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,875.44 3,228.13 2,712.33 2,822.63 2,736.23

Competitive Comparison of Amicus Therapeutics's Market Cap

For the Biotechnology subindustry, Amicus Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amicus Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's Market Cap falls into.


;
;

Amicus Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Amicus Therapeutics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )=Share Price (A: Dec. 2024 )*Shares Outstanding (EOP) (A: Dec. 2024 )
=€9.15*299.042
=€2,736.2

Amicus Therapeutics's Market Cap for the quarter that ended in Dec. 2024 is calculated as

Market Cap (Q: Dec. 2024 )=Share Price (Q: Dec. 2024 )*Shares Outstanding (EOP) (Q: Dec. 2024 )
=€9.15*299.042
=€2,736.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amicus Therapeutics  (FRA:AM6) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Amicus Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics Business Description

Traded in Other Exchanges
Address
47 Hulfish Street, Princeton, NJ, USA, 08542
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines